From Sweet to Sour: SGLT-2-Inhibitor-Induced Euglycemic Diabetic Ketoacidosis
Open Access
- 21 June 2024
- journal article
- review article
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 14 (7) , 665
Abstract
Sodium–glucose cotransporter 2 (SGLT-2) inhibitors are highly selective, effective, and generally well-tolerated antihyperglycemic agents targeting the SGLT-2 transmembrane protein. Despite being primarily registered for diabetes treatment, due to their cardiorenal protective properties, SGLT-2 inhibitors caused a paradigm shift in the treatment of other diseases on the cardiorenal spectrum, becoming a fundamental part of heart failure and chronic kidney disease management. With their rapidly increasing use, there are also increased reports of a rare, often under-recognised and potentially deadly side effect, SGLT-2-inhibitor-induced euglycemic diabetic ketoacidosis (EDKA). The primary pathophysiological process behind its multifactorial aetiology comprises glucosuria and osmotic diuresis, which produce a significant carbohydrate deficit, leading to an increase in the glucagon–insulin ratio, thus resulting in accelerated ketogenesis. Although EDKA has a similar clinical presentation as diabetic ketoacidosis (DKA), the absence of the high glucose levels typically expected for DKA and the presence of urine ketone reabsorption contribute to a significant delay in its recognition and timely diagnosis. Given the broad use of SGLT-2 inhibitors, increased awareness, early recognition, and prompt identification of precipitating factors are essential. In this narrative review, we comprehensively explore the pathophysiological mechanisms of SGLT-2-inhibitor-induced EDKA, analyse its clinical manifestation, and identify the most common triggers for its development. We also discuss EDKA management and preventive strategies.Keywords
This publication has 50 references indexed in Scilit:
- Cardiovascular and renal effects of SGLT2 inhibitor initiation in acute heart failure: a meta-analysis of randomized controlled trialsClinical Research in Cardiology, 2023
- Potential Clinical Applications for Continuous Ketone Monitoring in the Hospitalized Patient with DiabetesCurrent Diabetes Reports, 2022
- Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney DiseaseCurrent Diabetes Reports, 2022
- SGLT2-inhibitors; more than just glycosuria and diuresisHeart Failure Reviews, 2020
- Euglycemic KetoacidosisCurrent Diabetes Reports, 2020
- SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting SystemDiabetologia, 2017
- Treatment of Diabetic Ketoacidosis (DKA)/Hyperglycemic Hyperosmolar State (HHS): Novel Advances in the Management of Hyperglycemic Crises (UK Versus USA)Current Diabetes Reports, 2017
- Euglycemic ketosis in patients with type 2 diabetes on SGLT2-inhibitor therapy—an emerging problem and solutions offered by diabetes technologyEndocrine, 2017
- Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: Basic mechanisms and therapeutic perspectivesDiabetes/Metabolism Research and Reviews, 2017
- SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary LiteraturePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2017